Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.24 - $11.48 $61,800 - $86,100
-7,500 Reduced 23.15%
24,900 $268,000
Q2 2024

Aug 14, 2024

BUY
$6.01 - $9.04 $97,963 - $147,352
16,300 Added 101.24%
32,400 $273,000
Q1 2024

May 15, 2024

BUY
$4.38 - $9.02 $52,560 - $108,240
12,000 Added 292.68%
16,100 $108,000
Q4 2023

Feb 14, 2024

SELL
$4.06 - $10.08 $3,653 - $9,072
-900 Reduced 18.0%
4,100 $24,000
Q3 2023

Nov 14, 2023

BUY
$9.69 - $13.34 $39,729 - $54,694
4,100 Added 455.56%
5,000 $48,000
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.24 $32,505 - $43,692
-3,300 Reduced 78.57%
900 $10,000
Q1 2023

May 15, 2023

BUY
$10.04 - $15.5 $30,119 - $46,500
3,000 Added 250.0%
4,200 $45,000
Q4 2022

Feb 14, 2023

SELL
$10.65 - $14.84 $201,285 - $280,476
-18,900 Reduced 94.03%
1,200 $13,000
Q3 2022

Nov 14, 2022

SELL
$9.39 - $16.99 $939 - $1,698
-100 Reduced 0.5%
20,100 $300,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $597M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.